Suchergebnisse
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
Beam Therapeutics BEAM incurred a loss of $1.18 per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of $1.00. The company had reported a loss of $1.00 per


